Literature DB >> 8529188

Necromancing the stones.

V Goel.   

Abstract

Since its introduction 15 years ago extracorporeal shockwave lithotripsy (ESWL) has become a standard treatment for urinary stones. The author comments on the results of Adrian R. Levy and Maurice McGregor's study of the use of ESWL for urinary stones in Quebec (see pages 1729 to 1736 of this issue). The rapid increase in the use of ESWL that occurred in the first 2 years of the study points to the fact that the application of a new technology is often quickly expanded before thorough assessments of effectiveness and safety have been carried out. New technologies also lead to shifts in cost distribution that must be considered in cost analyses. The author argues that continuing research is needed to document the dissemination of new technologies and points to methodologic concerns that should be addressed to make such research as fruitful as possible.

Mesh:

Year:  1995        PMID: 8529188      PMCID: PMC1488182     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  5 in total

1.  Evolution of shock wave lithotripsy during its first decade.

Authors:  G W Drach
Journal:  J Urol       Date:  1992-09       Impact factor: 7.450

Review 2.  Kidney stones and lithotripters: critical analysis of the introduction of extracorporeal shock wave lithotripsy into Canada.

Authors:  L C Wiser; R H Plain; J B Dossetor
Journal:  CMAJ       Date:  1990-12-15       Impact factor: 8.262

3.  Epidemiology of renal stones in a middle-aged male population.

Authors:  S Ljunghall; H Hedstrand
Journal:  Acta Med Scand       Date:  1975-06

4.  Renal stone epidemiology: a 25-year study in Rochester, Minnesota.

Authors:  C M Johnson; D M Wilson; W M O'Fallon; R S Malek; L T Kurland
Journal:  Kidney Int       Date:  1979-11       Impact factor: 10.612

5.  Extracorporeally induced destruction of kidney stones by shock waves.

Authors:  C Chaussy; W Brendel; E Schmiedt
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.